Owner Scorecard


← All companies ← BNT Manual BORR → ← BIIB Biotechnology CADL →

BNTX, BioNTech SE American Depositary Share

Biotechnology consumer brand Unprofitable

Our multi-technology combination of platforms and product candidates aims to position us as pioneers in the field of individualized, patient-centric therapeutic approaches in oncology and infectious diseases.

Our approach has generated a robust and diversified product candidate pipeline across a range of technologies in oncology and infectious disease, and has led to the approval of our firs t marketed pharmaceutical product, Comirnaty .

Innovation is at the core of our company, and we see potential for our technologies to expand beyond oncology and infectious diseases.

Latest annual: FY2025 20-F · figures as filed, in EUR · 1 ADS = 1 ordinary share
BNTX · BioNTech SE American Depositary Share
I

The business

What it sells, where the money comes from, the kind of company it is.

Revenue · FY2025
€2.9B
+4.3% YoY · 43% 5-yr CAGR
Vital signs · TTM, with 5-yr average
Revenue €2.9B 5-yr avg €9.1B
Gross margin 78% 5-yr avg 82%
Operating margin −49.0% 5-yr avg 15.0%
Owner-earnings margin 14% 5-yr avg 48%
Free cash flow margin 10% 5-yr avg 44%

The business in brief

read the 10-K →

What this business is and what moves its needle, from its own SEC filings.

Situation
Unprofitable. No sustained operating profit across the record; an earnings multiple has nothing to rest on. What the record does show is revenue, the gross-margin trajectory, and the burn against the cash on hand.
What moves the needle
Operating margin has reached 81% at its best but run negative through the cycle (median −42%) on a 84% gross margin — so the question is which reading is truer: whether the median was pulled below zero by one-off charges, by the cycle, or by spending it is still growing into, and whether it settles back at a profit. Capital spending runs about 10% of sales, well above depreciation, so the return earned on what it sinks into that plant weighs as much as the margin. Read this kind of business on the pipeline against the patent cliff, and pricing. On its own account, the filing leans hardest on pricing power & competition, set against the numbers in what the filing emphasizes, below.
Is it a good business?
Return on capital has rarely cleared the cost of capital (median −10%, above 15% in 1 of 6 years). The steadier read is owner earnings: roughly 4% of revenue reaches owners as cash, though it swings, and customers and suppliers fund the business through negative working capital. This is price-taker territory, where the balance sheet and the cycle matter more than any multiple; the rest is in the 10-K.

Every line is arithmetic on the company's filings, shown in full in the sections below.

II

The record

Ten years of arithmetic, read across the cycle.

The record, 2017–2025

realized figures from each filing · older years to the left
2017’172018’182019’192020’202021’212022’222023’232024’242025’25TTMTTMDec 2025
Income statement
€62M€128M€109M€482M€19.0B€17.3B€3.8B€2.8B€2.9B€2.9BRevenueRevenue
85%89%84%88%85%83%84%80%78%78%Gross marginGross mgn
(€61M)(€54M)(€182M)(€82M)€15.3B€12.6B€690M(€1.3B)(€1.4B)(€1.4B)Operating incomeOp. inc.
−99.5%−42.2%−167.1%−17.1%80.5%73.0%18.1%−47.8%−49.0%−49.0%Operating marginOp. mgn
(€86M)(€48M)(€179M)€15M€10.3B€9.4B€930M(€665M)(€1.1B)(€1.1B)Net incomeNet inc.
32%27%22%Effective tax rateTax rate
Cash flow & returns
(€53M)(€59M)(€199M)(€14M)€890M€13.6B€5.4B€208M€456M€456MOperating cash flowOp. cash
€11M€22M€34M€39M€75M€123M€45M€46M€57M€57MDepreciationDeprec.
€23M(€33M)(€53M)(€67M)(€9.5B)€4.0B€4.4B€827M€1.5B€1.5BWorking capital & otherWC & other
€24M€30M€39M€66M€128M€329M€249M€287M€175M€175MCapexCapex
39.5%23.4%35.5%13.7%0.7%1.9%6.5%10.4%6.1%6.1%Capex / revenueCapex/rev
(€63M)(€81M)(€237M)(€52M)€815M€13.5B€5.3B€162M€399M€399MOwner earningsOwner earn.
−102.4%−63.4%−218.3%−10.8%4.3%77.7%139.5%5.9%13.9%13.9%Owner earnings marginOE mgn
(€77M)(€89M)(€237M)(€80M)€762M€13.2B€5.1B(€79M)€281M€281MFree cash flowFCF
−124.8%−69.6%−218.3%−16.5%4.0%76.5%134.1%−2.9%9.8%9.8%Free cash flow marginFCF mgn
€0€0€484M€0€0€0Dividends paidDiv. paid
-295%-16%149%6%-11%-10%ROICROIC
-18%-36%1%87%47%5%-3%-6%-230%Return on equityROE
1%87%45%5%−3%−230%Retained to equityRetained/eq
Balance sheet
€172M€412M€521M€1.3B€2.1B€14.1B€16.5B€16.8B€14.9B€14.9BCash & investmentsCash+inv
€19M€12M€166M€12.4B€7.1B€2.2B€1.5B€924M€924MReceivablesReceiv.
€6M€12M€64M€503M€440M€358M€283M€111M€111MInventoryInvent.
€102M€160M€204M€354M€427M€535M€535MAccounts payablePayables
€25M€24M€127M€12.7B€7.4B€2.2B€1.3B€500M€500MOperating working capitalOper. WC
€449M€560M€1.7B€15.1B€21.9B€19.5B€18.8B€16.1B€16.1BCurrent assetsCur. assets
€126M€138M€606M€3.5B€3.0B€2.1B€2.5B€2.1B€2.1BCurrent liabilitiesCur. liab.
3.6×4.1×2.8×4.3×7.4×9.4×7.5×7.5×7.5×Current ratioCurr. ratio
€3M€54M€58M€61M€363M€381M€368M€368MGoodwillGoodwill
€653M€798M€2.3B€15.8B€23.3B€23.0B€22.5B€22.0B€22.0BTotal assetsAssets
€74M€240M€302M€302MTotal debtDebt
(€447M)(€1.1B)(€1.8B)(€14.6B)Net debt / (cash)Net debt
-2.4×-1122.0×-90.8×-1.3×50.1×668.9×28.9×-48.0×-20.1×-20.1×Interest coverageInt. cov.
(€48M)€266M€493M€1.4B€11.9B€20.1B€20.2B€19.4B€19.2B€493MShareholders’ equityEquity
Per share
167M191M212M235M244M243M241M240M242M251MShares out (diluted)Shares
€0.37€0.67€0.51€2.05€77.77€71.15€15.87€11.44€11.87€11.42Revenue / shareRev/sh
€-0.51€-0.25€-0.85€0.06€42.18€38.78€3.87€-2.77€-4.70€-4.52EPS (diluted)EPS
€-0.38€-0.42€-1.12€-0.22€3.34€55.30€22.14€0.67€1.65€1.59Owner earnings / shareOE/sh
€-0.46€-0.47€-1.12€-0.34€3.12€54.45€21.29€-0.33€1.16€1.12Free cash flow / shareFCF/sh
€0.00€0.00€1.99€0.00€0.00€0.00Dividends / shareDiv/sh
€0.15€0.16€0.18€0.28€0.52€1.35€1.04€1.19€0.72€0.70Cap. spending / shareCapex/sh
€-0.29€1.40€2.33€5.83€48.74€82.43€84.15€80.75€79.54€1.96Book value / shareBVPS
Per-share growththe realized rate an owner's share compounded
8-yr5-yr
Revenue / share+54.3%/yr+42.1%/yr
Capital spending / share+22.2%/yr+20.9%/yr
Book value / share+68.7%/yr

The record, charted

FY2017–2025

Each measure over its full record; the current point and the worst year marked.

Share count
242Mpeak FY2021
ROIC
−10%low FY2019
Gross margin
78%low FY2025

Owner earnings vs. net income

Owner earningsNet income

The accountant's number, and the cash an owner can take; the gap is the tell.

€399Mowner earningsvs.(€1.1B)net incomelow FY2019

Where the cash went

ReinvestBuybacksDividendsAcquisitionsRetained

Each year's operating cash, by what management did with it: the mix, and how it drifts.

FY2021FY2025

Net income is the accountant's number; owner earnings is the cash an owner could take out. The walk between them, off the cash-flow statement, and whether the gap is widening or holding.

In fiscal 2025 the business earned €399M of owner earnings, the operating cash left after the €57M it takes just to hold its position. It put €118M more into growth; free cash flow, after that spending, was €281M.

FY2025FY2024FY2023FY2022FY2021
Reported net income(€1.1B)(€665M)€930M€9.4B€10.3B
Depreciation & amortizationnon-cash charge added back+€57M+€46M+€45M+€123M+€75M
Working capital & othertiming of cash in and out, other non-cash items+€1.5B+€827M+€4.4B+€4.0B−€9.5B
Cash from operations€456M€208M€5.4B€13.6B€890M
Maintenance capital expenditurethe spending needed just to hold position and volume−€57M−€46M−€45M−€123M−€75M
Owner earnings€399M€162M€5.3B€13.5B€815M
Growth capital expenditurediscretionary; spent to get bigger, not to stand still−€118M−€241M−€204M−€206M−€52M
Free cash flow€281M(€79M)€5.1B€13.2B€762M
Owner-earnings marginowner earnings ÷ revenue14%6%139%78%4%

Owner earnings is the cash an owner could pull out without starving the business: operating cash less the maintenance capital it must spend to hold its position (here about €57M, roughly its depreciation, the rate its assets wear out). The other €118M of its capital spending is growth it chose, not upkeep it owed; charged only with the maintenance it must do, the business earns well more than the year's free cash flow shows.

Maintenance capex is estimated as depreciation where a growing business invests above it; free cash flow is the figure the scorecard's free-cash margin reads.

III

Quality & stewardship

Returns, the balance sheet, capital allocation, and pay.

Owner’s Scorecard

FY2025 20-F · source on SEC EDGAR →

Will it survive?

  • Does not cover its interest
    Operating income (€1.4B) ÷ interest expense €70M
    What this means

    A full year of operating profit didn't cover the interest bill. This is the zombie zone: the business depends on refinancing, asset sales, or forbearance to service its debt.

  • Net cash
    Cash €7.7B + ST investments €7.2B − debt €302M
    What this means

    Cash and short-term investments exceed every dollar of debt by €14.6B, on net the company owes nothing, and can act from strength when others can't. Net debt is the leverage figure that matters: the cash is already set against the debt. Strategic or illiquid investments aren't counted here.

  • Negative, funded by others
    DSO 118 + DIO 63 − DPO 304 days
    What this means

    Days cash is tied up between paying suppliers and collecting from customers. A negative cycle is a quiet moat: suppliers and customers fund the operation (Buffett's “float”), the company grows on other people's money.

Is it a good business?

  • Not meaningful here
    Invested capital (€6.9B) = debt €302M + equity €493M − cash
    Industry peers: median 10%
    What this means

    Invested capital is near zero or negative, usually years of buybacks pulling equity down. ROIC explodes or flips sign and stops meaning anything. Judge this one on Owner Earnings instead.

  • Solid, recently turned positive
    latest €399M = operating cash €456M − maintenance capex €57M; positive each of the last 3 years, after an earlier loss stretch (9-yr median 4%)
    Industry peers: median 9%
    What this means

    What an owner could take out without starving the business: operating cash less the maintenance capital it must spend to hold its position — Buffett's owner earnings. That's 14% of revenue this year, a 4% median across 9 years. It chose to put €118M more into growth, so free cash flow this year was €281M — the gap is investment, not weakness.

  • Loss, but cash-generative
    Net income (€1.1B) · cash from operations €456M
    What this means

    The company reported a net loss, so a conversion ratio isn't meaningful. What matters then is whether operations still threw off cash, here, they did.

How is the cash used?

  • Reinvests most of it
    Dividends + buybacks €0 ÷ Owner Earnings €399M
    What this means

    Of €399M Owner Earnings, €0 (0%) went back to shareholders, €0 dividends, €0 buybacks. Returning most of it is the mark of a mature business with little left to reinvest at a high return; reinvesting most could mean a long runway, or empire-building. The split doesn't say which; the return earned on it (see ROIC) does.

  • Investing or harvesting? 3.06×
    Expanding
    Capex €175M ÷ depreciation €57M
    What this means

    Descriptive, not a grade. Above ~1× means investing faster than assets wear out (growth, or, sustained for years, today's earnings carrying less depreciation than tomorrow's will). Below means spending less than it's wearing out (efficiency, or a melting asset base). The ratio won't tell you which; the filings will.

Graham’s defensive tests · 2 of 4 met

Graham’s numerical criteria for the defensive investor (The Intelligent Investor, ch. 14), run on the filings. A floor of safety, not a buy signal; many fine modern businesses fail his strictest liquidity rules by design.

  • Adequate size
    Revenue ≥ $2B (a dollar floor) · €2.9B
    What this means

    Big enough to weather a storm. Graham's floor is a dollar figure — about $2B of revenue as a conservative modern stand-in. This company reports in its home currency and we carry no exchange rate, so we show the figure and leave the size bar for you to apply rather than convert it with a number we don't have.

  • Strong liquidity Pass
    Current ratio ≥ 2× · 7.54×
    What this means

    Current assets at least twice current liabilities, near-term bills covered without touching the business. Strict by design: many cash-rich modern firms run leaner and miss it, holding their cushion in longer-dated securities.

  • Conservative debt Pass
    Debt ≤ working capital · €302M vs €14.0B WC
    What this means

    Graham's rule that borrowings not exceed net current assets. Capital-heavy and buyback-heavy firms routinely fail it, read it next to interest coverage, not alone.

  • Earnings stability Miss
    A profit every year (9-yr record) · 5 loss years
    What this means

    Graham wanted earnings in each of the past ten years, the stability a defensive owner leans on.

  • Dividend record Miss
    Uninterrupted dividends · 1 of 9 yrs
    What this means

    An unbroken dividend was Graham's mark of durability. He wanted twenty years; the filings show about ten, and a single suspension breaks the streak. Non-payers, many fine modern compounders, fall outside his defensive net by design.

  • Earnings growth
    Earnings +33% over the record ·
    What this means

    Earnings were negative early in the record, a growth rate isn't meaningful.

  • Moderate price
    P/E ≤ 15 and P/E × P/B ≤ 22.5 · decided by the price
    What this means

    Graham's valuation gate, the wall he kept between a sound business and a sound investment. Three-year average earnings are €-1.15/share (latest year €-4.49), the averaged base the calculator's gate runs on, and book value is €1.95/share. Enter a price in “What the price implies” just below for the P/E, P/B, and whether it clears. But this is the rule Buffett outgrew: there's no hard P/E law, and a wonderful business can deserve a far richer multiple if the thesis holds, treat it as the bargain-hunter's floor, not a verdict on the price.

Durability & moat, 2017–2025

Whether the record’s returns held, and what the capital reinvested earned.

  • Profitable years 4 of 9
    What this means

    Lost money in 5 year(s), look at what happened there before trusting the average.

  • Return on capital ≥ 15% 1 of 3 yrs
    What this means

    A moat shows up as a high return on invested capital that holds year after year, not one good vintage.

  • Operating margin −103% → −26% (3-yr avg ends)
    What this means

    Through the cycle the operating margin widened — about −103% early to −26% lately, median −42% — pricing power intact or improving.

  • Reinvestment, incremental ROIC returns capital
    What this means

    The capital base barely grew: this business returns cash through dividends and buybacks rather than reinvesting. Judge it on the cash returned, not on compounding.

  • Worst year 2019 · −167.1% op. margin
    What this means

    Operations went underwater in 2019, understand why before trusting the good years.

  • Share count +4.7%/yr
    What this means

    The share count is rising, dilution works against you on a per-share basis.

  • Dividend record paid
    What this means

    Paid a dividend in 1 of the years on record.

  • How management talks about it Owner’s terms
    What this means

    The record and the register agree: capital is compounding and the filing reasons in an owner’s terms — per-share value, return on capital, the long term — not a promoter’s.

Does AI threaten the moat?

Low contestability

The moat is physical, regulated or balance-sheet-funded, the kind AI cuts costs within but does not contest.

In its own filing Named as a competitive risk

Its FY2025 10-K names artificial intelligence as a competitive threat.

“Following our acquisition of InstaDeep Ltd., or InstaDeep, we also face competition in the rapidly growing and developing artificial intelligence, or AI, industry.”

AI is unlikely to contest a moat that is physical, regulated or balance-sheet-funded; here it reads more as a cost tool than a threat, and the company is using it that way.

Read from the filing's own risk factors, paired with the industry's structure under its SIC code; the durability is read above, the price below.

All figures as filed; the source filing is linked above.

Current Position

as of fiscal year-end, Dec 31, 2025

Can the business pay what it owes this year, off the freshest balance sheet: the quality of the assets, the debt actually coming due, and what a low ratio means here.

Current assets€16.1B
  • Cash & short-term investments€14.9B
  • Receivables€924M
  • Inventory€111M
  • Other current assets€235M
Current liabilities€2.1B
  • Debt due within a year€130M
  • Accounts payable€535M
  • Other current liabilities€1.5B
Current ratio7.54×all current assets ÷ what's due · Graham looked for 2×
Quick ratio7.49×stricter: inventory excluded
Cash ratio6.94×strictest: cash alone against what's due
Working capital€14.0Bthe cushion left after near-term bills
Debt due this year vs. cash€130M due · €14.9B cash covered by cash on hand, no refinancing forced · both figures from the Dec 31, 2025 balance sheet
Deeper floors
Tangible book value€126Mequity stripped of goodwill & intangibles
Net current asset value€13.4BGraham's net-net: current assets less all liabilities
Debt incl. operating leases€532M€230M of it operating leases
Deferred revenue€755Mcustomer cash collected before delivery; operating float

From the company's latest filing.

How the cash was used, 2017–2025

Over the record, the business generated €20.2B of operating cash; how management split it reads as a cash builder, a large share of cash simply built up on the balance sheet.

  • Reinvested€1.3B · 7%
  • Dividends€484M · 2%
  • Retained (debt / cash)€18.4B · 91%
  • Returned to owners€484M

    2% of the owner earnings the business produced over the span, €484M as dividends and €0 as buybacks.

  • Source of fundingOperating cash

    Operating cash covered reinvestment and returns; over the span cash and short-term investments rose €14.7B.

  • Net change in share count50.7%

    The diluted count rose from 167M to 251M: issuance (stock pay, deals) outran any buybacks, so owners were diluted on net.

  • Dividend record€0.00/sh

    Paid in 1 of the years on record. It was cut at least once along the way.

  • Return on what it retained12%

    Of the earnings it kept rather than paid out (€18.1B over the span), annual owner earnings (first three years vs last three) grew €2.1B, so each retained €1 added about 0.12 of yearly owner earnings. Buffett's test, run on owner earnings instead of market value.

Buybacks are gross of stock issued to staff; the share-count line above is the net of that, the figure that decides whether owners gained. The average price paid blends a year of purchases (and any accelerated repurchase), so it is close, not exact. The record of where the cash went and on what terms.

Inverting the record

Invert: instead of why BioNTech SE American Depositary Share is a good business, the question is what would make owning it a mistake, and whether those marks are in the record. Disconfirming tests across 2017–2025.

1 of the 3 tests turned up something to look into; the other 2 came back clean.

  • Look hereDid the share count rise anyway?50.7%

    Diluted shares grew 50.7% over 2017–2025. Owners were diluted on net; each share owns less of the business than it did. Read the buyback line beside this one, not on its own.

And these came back clean
  • Is it less profitable than it was?
  • Did reported profit become cash?

Each test is read from the filings and is noisy alone; a flag can mark a cyclical trough or a year of heavy investment as easily as a problem. The filing says which.

Peers, Biotechnology

The same industry, side by side on owner economics. Each figure is a through-cycle median, so a peak or trough year can’t distort it; the group median at the foot is the line to read each against.

CompanyRevenueGross marginOp. marginROICOwner earn. margin
BMRNBioMarin$3.2B78%-1.7%-1%1%
AMRXAmneal Pharmaceuticals Inc.$3.0B37%7.9%3%9%
BNTXBioNTech SE American Depositary Share€2.9B84%-42.2%-10%4%
NBIXNeurocrine$2.9B99%11.2%10%21%
QDELQuidelOrtho$2.7B4.6%24%2%
EXELExelixis Inc.$2.3B96%23.9%18%34%
MRNAModerna Inc.$1.9B55%-126.4%-35%-77%
HALOHalozyme$1.4B83%37.1%17%39%
Group median83%6.3%7%7%
IV

The price

What a price has to assume.

What the price implies

reverse-DCF

Enter the US price, in dollars: the NYSE/Nasdaq quote you hold. Per the filing's own cover, “American Depositary Shares, each Representing one ordinary”; BioNTech SE American Depositary Share reports in EUR, so every figure in this tool is stated per ADS and translated at EUR 1 = $1.145 (2026-07-17, reference rate) so your dollar quote reconciles exactly. The record tables elsewhere on this page remain as filed, in EUR.

Type today's close and see the owner-earnings growth you'd have to believe to justify it, beside what BioNTech SE American Depositary Share has delivered.

$
Base

The assumptions

9.0% = the 4.55% 10-year Treasury (Jul 15, 2026) + 4.45 points of equity premium. The rate you require is yours to set.

Enter a price above to run it.

Implied by the price
Owner-earnings growth · ’21→’25−55%/yr
Owner-earnings growth, delivered
Owner-earnings yield
P/E (3-yr earnings ’23–’25)
P/B
Graham’s price gate

Graham capped the multiple at 15×; Buffett and Munger let that rule go: a wonderful business can deserve 50× if the thesis holds. The gate marks the bargain-hunter's floor.

Against a high-grade bond: Graham’s yardstick bond yield%

Prefilled with the 10-year Treasury (4.55%, as of Jul 15, 2026). Edit it for today’s exact figure, or a AAA corporate yield.

Graham measured a stock against the bond you could own instead, the heart of his margin of safety. Enter a price above to weigh the owner-earnings yield against this bond.

Free cash flow $322M on 253M shares outstanding, per the 20-F/A cover, as of 2026-03-27; net cash $16.7B. The base is the latest year by default; Normalize values it on the through-cycle median owner-earnings margin (to avoid paying on a peak year). Net of stock comp treats option pay as the expense it is. Capex ($200M) runs well above depreciation ($65M), so this is a build-out; Steady-state swaps total capex for maintenance (≈ depreciation), lifting the base to about $457M, the cash it would throw off if it stopped expanding. The dials set the multiple a growth belief justifies; the price, and every dollar on this page, is yours.

Cite: Owner Scorecard, "BioNTech SE American Depositary Share (BNTX), the owner's record," https://ownerscorecard.com/c/BNTX, data as of 2026-07-09.

Manual order: ← BNT its page in the Manual BORR →

Industry order: ← BIIB the Biotechnology chapter CADL →